Bristol-Myers Squibb (BMS) and Exelixis are to collaborate on the development of two of Exelixis’ novel clinical-stage anticancer compounds, XL184 and XL281. GlaxoSmithKline turned down an option to develop the products in October, returning full rights to Exelixis and allowing the biotech’s long-term partner, BMS, to step in.